EUR/USD likely to find a peak near 1.25: UBS
Tuesday, Jasper Therapeutics (NASDAQ:JSPR), currently trading at $6.08 with a market capitalization of $91.21 million, maintained its Market Outperform rating and $70.00 price target from JMP Securities. The firm's analyst expressed a cautiously optimistic stance on the company's lead candidate, briquilimab, in comparison to a competing product from Celldex Therapeutics (NASDAQ:CLDX). According to InvestingPro data, the stock's RSI suggests it's in oversold territory, potentially indicating a favorable entry point for investors.
Jasper Therapeutics' stock rating comes amid evaluations of briquilimab's potential in the market. While JMP Securities suggests that the current investor sentiment reflects low expectations for the drug, InvestingPro analysis shows the company maintains a strong liquidity position with a current ratio of 7.61, providing runway for drug development. However, the company is quickly burning through cash, a critical factor for investors to monitor.
The analyst noted that improvements in the 180mg UAS7 results and consistent safety in the 240mg Q8W regimen could significantly alter the market's perception of briquilimab. These developments would challenge the current assumption of a mere 10% market-implied probability of success for the drug.
Additionally, JMP Securities anticipates an incremental update at the upcoming AAAAI meeting, which is expected to provide about one month of additional dosing and follow-up from patients included in the January update. The firm also highlighted the opportunity for Jasper Therapeutics to engage with healthcare professionals and present further data at this event.
A more substantial update on briquilimab's progress is expected in mid-2025, which could be pivotal for Jasper Therapeutics. The firm's current outlook remains positive, with the $70.00 price target suggesting a strong conviction in the potential success of briquilimab. Investors should note that the company's next earnings report is scheduled for March 5, 2025. For deeper insights into Jasper's financial health and additional ProTips, consider accessing the comprehensive research report available on InvestingPro.
In other recent news, Jasper Therapeutics experienced a series of analyst adjustments following the release of initial data from the BEACON study. RBC Capital Markets lowered its price target for the company to $48.00, maintaining an Outperform rating, and noted the positive efficacy signs at the 240 mg dose. Similarly, BTIG adjusted its price target to $64, sustaining a Buy rating, and highlighted promising results from a 240mg single-dose of briquilimab.
H.C. Wainwright also confirmed a Buy rating and a $40.00 price target, based on an evaluation of briquilimab's competitive potential. Meanwhile, BMO Capital Markets maintained an Outperform rating with a steady price target of $63.00, expressing continued optimism despite the stock's recent decline.
On the other hand, Citi maintained a Buy rating and $70.00 price target on Celldex Therapeutics, suggesting that Jasper's findings do not present a clear threat to Celldex's positioning in the CSU market. These recent developments underscore the ongoing assessments of Jasper Therapeutics' valuation and the potential benefits and risks of its drug, briquilimab.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.